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Abstract
APE1 is the major nuclease for excising abasic (AP) sites and particular 39-obstructive termini from DNA, and is an integral
participant in the base excision repair (BER) pathway. BER capacity plays a prominent role in dictating responsiveness to
agents that generate oxidative or alkylation DNA damage, as well as certain chain-terminating nucleoside analogs and 5-
fluorouracil. We describe within the development of a robust, 1536-well automated screening assay that employs a
deoxyoligonucleotide substrate operating in the red-shifted fluorescence spectral region to identify APE1 endonuclease
inhibitors. This AP site incision assay was used in a titration-based high-throughput screen of the Library of
Pharmacologically Active Compounds (LOPAC
1280), a collection of well-characterized, drug-like molecules representing all
major target classes. Prioritized hits were authenticated and characterized via two high-throughput screening assays – a
Thiazole Orange fluorophore-DNA displacement test and an E. coli endonuclease IV counterscreen – and a conventional,
gel-based radiotracer incision assay. The top, validated compounds, i.e. 6-hydroxy-DL-DOPA, Reactive Blue 2 and myricetin,
were shown to inhibit AP site cleavage activity of whole cell protein extracts from HEK 293T and HeLa cell lines, and to
enhance the cytotoxic and genotoxic potency of the alkylating agent methylmethane sulfonate. The studies herein report
on the identification of novel, small molecule APE1-targeted bioactive inhibitor probes, which represent initial chemotypes
towards the development of potential pharmaceuticals.
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Introduction
Most drugs employed to eradicate neoplastic disease (e.g.
alkylators, cross-linking agents, topoisomerase inhibitors and
certain antimetabolites) operate by introducing DNA lesions/
intermediates that block replication of rapidly dividing cells, such
as cancer cells, and activate cell death responses [1]. Alkylators, for
instance, induce cell killing through the formation of alkylated
bases, many of which are either lost spontaneously to form abasic
sites or are substrates for DNA glycosylases [2] (see below). A
primary goal of current studies is to devise combinatorial methods
that (a) protect normal cells from the toxic effects of anti-cancer
agents and (b) enhance the sensitivity of tumor cells. As DNA
repair systems represent a major protective mechanism against the
cytotoxic effects of clinical DNA-interactive compounds, recent
efforts have focused on the design of novel small molecule
inhibitors of DNA repair proteins, e.g. the DNA strand break
response protein poly(ADP)ribose polymerase PARP1 [3,4].
BER is the major pathway for dealing with spontaneous
hydrolytic, oxidative and alkylative base and sugar damage to
DNA [5]. Central to this process is incision at an apurinic/
apyrimidinic (AP) site, which is generated either spontaneously or
via the enzymatic activity of a DNA repair glycosylase. The
ensuing strand cleavage step is performed by the main, if not sole,
mammalian AP endonuclease, APE1 [6,7]. Significantly, APE1
has been found to be essential for not only animal viability, but
also for cell viability in culture [8,9]. Moreover, past studies
incorporating either antisense or RNAi strategies have revealed
that APE1-deficient cells exhibit hypersensitivity to a number of
‘‘DNA-damaging’’ agents, including the laboratory chemicals
methyl methanesulfonate (MMS) and hydrogen peroxide, and the
anticancer agents ionizing radiation, thiotepa, carmustine, temo-
zolomide, gemcitabine, and the nucleoside analogue troxacitabine
[10]. Recent work from our group employing a dominant-negative
APE1 protein (termed ED), which binds with high affinity to
substrate DNA and blocks subsequent repair steps [11], has shown
that ED augments the cell killing of 5-fluorouracil and 5-
fluorodeoxyuridine, implicating BER in the cellular response to
such antimetabolites as well (McNeill et al., in press) [12]. These
data underscore the potential of APE1 as a target for inhibition in
the effort to improve therapeutic efficacy of clinical DNA-
interactive drugs via inactivation of DNA repair responses [1].
Two groups have recently reported on the isolation of APE1
inhibitors using a high-throughput screening (HTS) approach.
However, in the first instance [13], the reported effectiveness of
this compound (i.e. CRT0044876 or 7-nitro-1H-indole-2-carbox-
ylic acid) has not been reproduced [14]. In the second case, the
small molecules (i.e. arylstibonic acids) when used in culture did
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increased sensitivity to the alkylating agent MMS [15]. Further-
more, antimony-containing compounds are generally considered
undesirable from a probe development standpoint due to their
possible promiscuity akin to the effect of heavy metal ions and
their occasional high toxicity [16]. Thus, there is a need for
improved biochemical, and effective biological, inhibitors of
APE1. BER inhibitors or activators would provide novel resources,
not only for basic science purposes, but for the potential
development of high affinity targeted, therapeutics that may
improve the efficacy of treatment paradigms by promoting
selective sensitization of diseased cells or increasing the protection
of normal cells, respectively.
Methods
Reagents
Thiazole Orange (ThO), Tris-HCl, Tween-20, EDTA, NaCl,
MgCl2 and dithiothreitol (DTT) were purchased from Sigma–
Aldrich. Dimethyl sulfoxide (DMSO, certified ACS grade) and
arylstibonic inhibitors (NSC-13744, NSC-13793, NSC-15596, and
NSC-13755) were obtained from Fisher, Inc. and the National
Cancer Institute Developmental Therapeutics Program Natural
Products Repository, respectively. Black solid-bottom 384-well and
1536-well plates were purchased from Greiner Bio One (Monroe,
NC).
Compound library
The Sigma-Aldrich Library of Pharmacologically Active
Compounds (LOPAC
1280) were received as 10 mM DMSO stock
solutions and were arrayed for screening as plate-to-plate (vertical)
dilutions at 5 mL each in 1536-well Greiner polypropylene
compound plates by following previously published methods
[17,18].
Enzymes and fluorogenic substrates
Recombinant human APE1 and E. coli EndoIV were purified as
previously described [19]. Deoxyoligonucleotides containing a
tetrahydrofuran (THF) AP site analog, carboxytetramethyl
rhodamine (TAMRA), or Black Hole Quencher-2 (BHQ-2), as
appropriate (see Figure 1), were purchased from Biosearch
Technologies, Inc., (Novato, CA). To create double-stranded
DNA substrates, equal volumes of 200 mM solutions of the
respective strands in reaction buffer were mixed and incubated at
95uC for 5 min. The annealing mixture was allowed to cool
gradually to room temperature. Annealing and assay experiments
were performed in the following buffer: 50 mM Tris pH 7.5,
25 mM NaCl, 2 mM MgCl2, 1 mM DTT, 0.01% Tween-20.
Assay development and optimization
Initial optimizations were carried out in 384-well format at a
40 mL total reaction volume. Briefly, 30 mL of APE1 were pipetted
into the plate and incubated at room temperature for 10 min;
subsequently, 10 mL of substrate were added to start the reaction.
The final assay concentrations of the enzyme and substrate were
0.75 nM and 50 nM, respectively. Kinetic fluorescence data were
collected on a ViewLux high-throughput CCD imager (Perkin
Elmer, Waltham, MA) equipped with standard FITC (excitation
filter 480 nm and emission filter 530 nm) or BODIPY (excitation
filter 525 nm and emission filter 598 nm) optics.
qHTS protocol and data analysis
Three ml of reagents (buffer in columns 3 and 4 as negative
control and APE1 in columns 1, 2, 5–48) were dispensed into a
1536-well plate. Compounds (DMSO solutions) and control
(DMSO only) (23 nL) were transferred via Kalypsys pintool
equipped with 1536-pin array. The plate was incubated for
15 min at room temperature, and then 1 mL of substrate (50 nM
final concentration) was added to start the reaction. Library plates
were screened from the lowest to highest concentration.
Screening data were corrected and normalized, and concen-
tration–effect relationships were derived by using in-house
developed, publicly available algorithms (http://www.ncgc.nih.
gov/pub/openhts/curvefit/). Percent activity was computed after
normalization against the uninhibited, or neutral, control (64
wells, entire columns 1 and 2) and the no-enzyme, or 100%
inhibited, control (64 wells, entire columns 3 and 4), respectively.
A four parameter Hill equation was fitted to the concentration-
response data by minimizing the residual error between the
modeled and observed responses.
Radiotracer incision assay
The radiotracer assay was performed essentially as described
[20]. In brief, prioritized candidate inhibitor compounds from the
qHTS assay were incubated at various concentrations (100 mM
data shown) with APE1 (100 pg) at room temperature for 15 min in
25 mM Tris pH 7.5, 25 mM NaCl, 1 mM MgCl2, 1 mM DTT
and 0.01% Tween-20. At that time, 0.5 pmol
32P-radiolabeled
THF-containing 34 mer double-stranded DNA substrate [21] was
added. Incision reactions were then carried out immediately at
37uC for 10 min in a final volume of 10 mL. After the addition of an
equal volume of stop buffer (0.05% bromophenol blue and xylene
cynol, 20 mM EDTA, 95% formamide), the radiolabeled substrate
and product were separated on a standard polyacrylamide
denaturing gel and quantified by phosphorimager analysis [21].
ThO dye-displacement assay [22]
During initial optimization, 50 nM of the unlabeled version of
the red substrate (Figure 1) was titrated with ThO in 40 mL in 384-
well format; 250 nM ThO was selected for subsequent tests. For
compound profiling, the assay was miniaturized to 4 mL in a 1536-
well plate by direct volume reduction. Compounds were added to
a4mL mixture of 50 nM DNA and 250 nM ThO via pintool
transfer and the fluorescence signal (excitation 480 nm, emission
530 nm) was measured after a 15 min incubation at room
temperature.
E.coli Endonuclease IV (EndoIV) profiling assay
EndoIV enzyme and substrate (same as that used with APE1)
optimization tests were initially performed at a 40 mL final volume
in a 384-well format. Reaction concentrations of 2 nM EndoIV
and 50 nM DNA substrate were selected for subsequent
experiments. For running the assay in 1536-well format, the same
protocol as described for APE1 above was followed.
Whole cell extract assay
HEK 293T or HeLa cells – maintained in DMEM with 10%
fetal bovine serum and 1% Penicillin-Streptomycin – were
harvested, washed with 16 PBS, re-suspended in cold 222 mM
KCl, incubated on ice for 30 min, and clarified by centrifugation
at 12,0006g for 15 min at 4uC [23]. The supernatant (whole cell
extract) was retained, the protein concentration determined using
the Bio-Rad Bradford reagent, and aliquots were stored at 280uC.
AP endonuclease activity assays were performed with or without
candidate inhibitor compounds as described above, except 60 ng
HEK 293T or 80 ng of HeLa whole cell extract was used.
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To measure colony survival, HeLa cells were plated in 6-well
plates 12–20 hr prior to treatment. Cells were treated as follows: (i)
exposed only to control medium, (ii) exposed to 0.25 mM MMS
alone for 1 hr, (iii) exposed to 1 or 5 mM of the indicated inhibitor
compound alone for 4 hr, or (iii) exposed to inhibitor compound
alone for 3 hr and then with MMS for an additional 1 hr at 37uC.
Following treatment, cells were washed once with 16 PBS and
incubated in regular maintenance media (DMEM, 10% FBS) at
37uC for 10–15 days. Colonies formed were fixed in methanol,
stained in methylene blue (Sigma), and counted to determine
percent survival relative to the untreated controls.
AP site measurement
HeLa cells were treated as above, except only at 5 mM inhibitor
where indicated. Following exposure, chromosomal DNA was
Figure 1. Incision assay. A) APE1 incises 59 to the abasic site analog (THF) to liberate a short 59-fluorophore donor (D)-labeled
deoxyoligonucleotide, causing increased fluorescence signal. D can be any fluorophore, and Q represents any compatible quench moiety. The
APE1 incision site is indicated by the arrow. The right side of the duplex is not complete, as denoted by the squiggly lines. B) Comparison of assay
performance for green (triangles) and red (squares) substrates. Kinetic time course assay was run at room temperature at 50 nM substrate in
duplicate with (filled symbols) or without (empty symbols) 0.75 nM APE1. The nucleotide sequence of the duplex substrates is in panel C, sub1, with
the 59 fluorophore and 39 quench incorporated as indicated. C) Sequence optimization of red-shifted substrates. Shown are the fold signal changes
after a 30 min reaction (S:B ratio), the maximum raw-fluorescence reaction signals obtained from 50 nM substrate incubated with 0.75 nM APE1, and
the raw-fluorescence signals observed from 50 nM of single-stranded TAMRA-labeled deoxyoligonucleotide (ssDNA, unquenched strand). The
nucleotide composition of sub1 through sub6 is indicated to the right. Note that sub6 is identical to that employed by Stivers [15].
doi:10.1371/journal.pone.0005740.g001
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DNA Damage Quantification Kit from Dojindo Molecular
Technologies,Inc.(Gaithersburg,MD)aspreviouslydescribed [11].
Molecular modeling
The preparation of the ligand for docking was performed using
OMEGA version 2.3.1, part of the OpenEye Scientific Software
suite (http://www.eyesopen.com/). Multiple low-energy confor-
mations of the ligands were generated and partial charges were
assigned to the ligand using MMFF94 force field [24]. The RMS
threshold between different conformers of OMEGA was set to
0.5 A ˚. A total of 137 conformers were generated for DL-DOPA.
DNA-bound crystallographic structure of APE1 was prepared for
the docking studies using MOE molecular modeling software
(http://www.chemcomp.com/). DNA strand has been cleaved at
the phosphodiester bond to leave sugar-phosphate backbone at a
position 59 of AP active site as the reference ligand for docking. All
hydrogens were added to the protein and partial charges were
attributed to the protein atoms using Amber99 force field [25].
The active site of APE1 in which the sugar phosphate binds was
characterized using FRED docking preparation program fred_re-
ceptor (http://www.eyesopen.com/) to generate optimal binding
pose within the active site defined by the user. First, during an
exhaustive docking, a pose ensemble is generated by rigidly
rotating and translating each conformer within the active site. All
surviving poses are scored with a scoring function (Chemgauss3)
and the top 100 poses are passed to optimization. Next, a
systematic solid body optimization is done by rigidly rotating and
translating the poses at half the step size used in the exhaustive
docking. Chemgauss3 is used in this step to score the poses during
optimization. Lastly, poses are ranked via consensus structure
method, in which the poses with the top consensus scores of
Shapegauss, PLP, Chemgauss2 and Chemgauss3 are retained, and
all other poses are discarded. Optionally after consensus scoring,
poses can be refined using the Merck Molecular Mechanics Force
Field. The refinement consists of full coordinate optimization of all
ligand atoms, and any poses that violate the constraints are
discarded after the refinement.
Results
AP endonuclease assay design and optimization
The starting point for our assay was the recently published
donor/quencher-based approach described by the laboratories of
Hickson and Stivers [13,15]. In their experiments, a deoxyoligo-
nucleotide containing an internal THF abasic site analog and a 59
6-carboxyfluorescein (FAM) label was annealed to a complemen-
tary strand with a 39 DABCYL quencher to create a double-
stranded DNA substrate. The close proximity of the fluorophore
and the quencher results in a dampened signal upon light
excitation. Following DNA backbone cleavage by APE1 [20], a
short deoxyoligonucleotide fluorophore-labeled product is sponta-
neously released from the remaining DNA fragment possessing the
quencher, causing the fluorophore emission to increase (Figure 1A).
However, the FAM/DABCYL format suffers from compound
fluorescent interference, which is readily evident in the fluorescein
(hereafter referred to as ‘‘green’’) spectral region. Therefore, we
proceeded to test red-shifted APE1 substrates (hereafter referred to
as ‘‘red’’ substrates) by utilizing a combination of carboxytetra-
methyl rhodamine (i.e. TAMRA) as the fluorophore donor and
BHQ-2 [26] as the matching quencher. This arrangement
operates in the red-shifted spectral region, where very few
compound library members have been noted to fluoresce [27].
As evident from Figure 1B, the red substrate exhibited near-
identical cleavage kinetics with APE1, but provided an approx-
imately twofold better signal increase, in comparison with the
green version.
APE1 exhibits little substrate sequence specificity [28], as it must
operate on abasic sites throughout the genome. Since we had the
ability to modify the nucleotide sequence at will, we designed and
tested several variations of the THF-containing red substrate to
identify the optimal arrangement for the screening assay. In total,
six substrates were examined, with their designations (sub1
through sub6) and composition indicated in Figure 1C. These
substrates were compared to a red-shifted version (sub6, Figure 1C)
of the previously published green substrate of Stivers [15]. The
fold signal changes after a 30 min reaction, as well as the
maximum reaction signals and the signal at 50 nM of single-
stranded TAMRA-labeled deoxyoligonucleotide, were compared.
Substrate 2 exhibited the greatest signal increase as a result of
APE1 cleavage, likely due to its optimal G/C content for maximal
quenching of the fluorophore and 59 length for dissociation after
incision (Figure 1C), and was thus selected for all subsequent
studies. We note that substrate 6 yielded the smallest signal
increase, mainly due to a higher baseline signal that likely arose
from ‘‘wobbling’’ of the shorter and more AT-rich upstream
portion.
Red substrate 2 (hereafter referred to as substrate) was further
evaluated in 384-well plates by recording the initial reaction rates
as a function of substrate concentration. From these studies (data
not shown), a Km value of 65 nM was estimated. The similarity in
Km obtained for substrate 2 here with the values reported
previously using a traditional radiolabeled substrate [29] served as
an additional validation of the present fluorogenic red-shifted
format. A substrate concentration of 50 nM was chosen for the
subsequent quantitative HTS (qHTS) experiments.
qHTS of the Library of Pharmacologically Active
Compounds (LOPAC
1280)
After further assay miniaturization to a 4 mL volume in a 1536-
well format (see Methods), a set of recently-reported known APE1
inhibitors, i.e. the arylstibonic acid derivatives [15], were obtained
from the National Cancer Institute and tested as controls; robust
concentration-dependent, fluorophore-independent inhibition was
observed (Figure S1). In addition, the IC50 values found here were
similar to the values previously obtained for the arylstibonic acid
derivatives [15] despite the differences in assay conditions (enzyme
and magnesium concentration, as well as substrate sequence
disparity), further verifying the functionality of our approach.
Figure S2 demonstrates that the assay reagents, as formulated at
their screening concentrations, were stable over a 24 hr period.
This stability, coupled with the robust assay performance in the
1536-well plate format, indicates that the enzyme is screenable in
an automated, unattended fashion.
The optimized APE1 assay was utilized in a qHTS of the
LOPAC
1280, which is composed of a range of drug-like bioactive
molecules representing all major target classes. The library was
screened in a dose response format at compound concentrations
ranging from 2 nM to 57 mM [17,18,30]. At the end of the screen,
data were analyzed and an average Z’ factor of 0.86 was
determined. Importantly, the Z’ factor [31] remained essentially
constant throughout the screen (Figure 2A), supportive of a highly
stable assay. In addition, control titrations with the arylstibonic
acid derivative NSC-13755 (see Figure S1), which were present in
column 2 of every screening plate, produced high-quality,
concentration-response curves, with the associated IC50 remaining
nearly constant as the screen progressed (Figure 2A). The
Bioactive Inhibitors of APE1
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corroborating a stable run.
The screen yielded a wide range of inhibitor responses (see
PubChem BioAssay Summary, AID 1705). Twelve compounds
were characterized by complete concentration-response curves
and IC50 values better than 5 mM (Figure 2B). Additionally, 44
samples yielded incomplete, single-point, top-concentration inhib-
itory responses. A large fraction of these latter compounds were
noted to possess hydrophobic functionalities, which are frequently
associated with propensity to aggregate or precipitate; these hits
received a low priority going forward. Only one strongly
fluorescent hit, idamycin, also known as idarubicin [33], was
noted.
Aurintricarboxylic acid (ATA) was identified as the most potent
inhibitor of APE1 in the LOPAC collection (Figure 2B).
Additional hits included a wide variety of small molecule
bioactives: cephalosporin type antibiotics (cephapirin sodium and
ceftriaxone sodium), the wide-acting flavonoid myricetin, the
purinoceptor antagonist Reactive Blue 2, the DNA-binding
anticancer drug mitoxantrone, the nitrosoaniline type protein
tyrosine phosphatase inhibitor methyl-3,4-dephostatin [34], the
antimycobacterial and antitrypanosomal fatty acid synthesis
inhibitor thiolactomycin [35], and the dopamine precursor 6-
hydroxy-DL-DOPA. Figure 3 shows the chemical structures of the
candidate APE1 inhibitors, prioritized based on the following
criteria: low or sub mMI C 50 value, chemical diversity, and not
likely fluorescent. Top active compounds were confirmed by re-
testing of independently procured powder samples in the HTS
assay and subjected to the investigations described next.
Validation and profiling assays
DNA binding. To screen out compounds that inhibit APE1
activity via non-specific DNA binding, we employed a fluorescent
dye displacement assay essentially as described by Boger [22]. The
principle behind the assay is that if a compound acts non-
specifically by associating with DNA, it will displace a DNA bound
flourophore, consequently decreasing the signal reading of the
sample. In order to arrive at the most optimal assay with respect to
the signal window and minimal interference from compound
autofluorescence, we compared the performance of ethidium
bromide, the dye most commonly used in this assay, to ThO, in
side-by-side titration experiments using an unlabeled version of the
optimized APE1 substrate (Figure 1C). ThO, which binds non-
covalently to DNA with high affinity, was selected as the
Figure 2. LOPAC
1280 qHTS. A) Robust screen performance as evidenced by the reproducible, high Z’ factor as a function of screening plate
number (solid squares) and stable IC50 values for the arylstibonic derivative NSC-13755 used as a control in each screening plate (solid circles). B)
Examples of representative concentration-response curves associated with a set of actives (denoted) identified in the screen.
doi:10.1371/journal.pone.0005740.g002
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found to offer superior signal (Figure 4A) and because its
fluorescence excitation and emission are red-shifted relative to
those of ethidium bromide, thus ensuring reduced susceptibility to
compound autofluorescence.
The ThO displacement assay was used to profile the
LOPAC
1280 collection in a dose-response format (see PubChem
BioAssay Summary, AID 1707). The well-documented DNA-
binding anticancer agents, idarubicin and doxorubicin, exhibited
strong ThO displacement profiles (data not shown), validating the
utility of the approach. Among the top APE1-active compounds
identified in the initial HTS, WB 64 and mitoxantrone
(representative plot shown in Figure 4B, right) were positive in
the DNA-binding assay, suggesting that they likely act as non-
competitive inhibitors (summarized in Figure 3). Thiolactomycin is
shown in Figure 4B (left) as an example of a compound that
inhibits APE1 activity, but does not affect ThO displacement.
EndoIV profiling screen. As another means of probing the
selectivity of the candidate APE1 inhibitors (Figure 3), we
miniaturized to a 1536-well format a qHTS assay for E. coli
EndoIV [19] utilizing the same THF-containing red substrate as
above (Figure S3). E. coli EndoIV, while exhibiting similar
biochemical activities to APE1, such as AP site incision, has no
sequence or structural homology to the human protein [36], and
thus, serves as a powerful protein counterscreen to identify APE1
specific affectors. A qHTS of the LOPAC
1280 collection (see
Methods) revealed considerably fewer inhibitors for the bacterial
enzyme (see PubChem BioAssay Summary, AID 1708). In fact,
there were only 5 complete concentration-response curves for
EndoIV, although as with APE1, a number of suspected
aggregators or insoluble compounds displayed inhibition only at
the top concentration. Furthermore, most of the EndoIV hits
functioned at a significantly higher IC50 than seen for APE1.
Mitoxanthrone (representative plot shown in Figure 5), WB 64,
Tyrphostin AG 538 and cephapirin sodium were similarly potent
against each endonuclease (summarized in Figure 3). The uniform
activity of mitoxantrone and WB 64 can be rationalized by their
DNA binding affinity as determined in the ThO displacement
assay (see above). Top APE1 hits, which were completely inactive
or weakly active against EndoIV, included ATA, 6-hydroxy-DL-
Figure 3. Top screening hits for APE1. The activities of the compounds shown (
a,I C 50 in mM,
b, inhibition detected (Yes) or not detected (No)) are
given for the primary screen (qHTS), radiotracer incision assay (Gel), ThO dye-displacement assay (TO), and E. coli EndoIV profiling (EndoIV). ND, not
determined. Me=methyl.
doi:10.1371/journal.pone.0005740.g003
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myricetin, methyl 3,4-dephostatin and Reactive Blue 2.
Radiotracer assay. As a means of further validating the
initial APE1 inhibitors (Figure 3), we simultaneously determined
the effect of the top actives on APE1 incision activity using a
32P-
based oligonucleotide radiotracer assay (see Methods). The top
APE1 hits were tested initially at 100 mM (Figure 6) and later by
determining the approximate IC50 values using a range of
Figure 4. ThO displacement assay. A) Assay optimization using either ethidium bromide (EthBr, left) or ThO (right) as the DNA bound
fluorophore. Plotted are raw fluorescence signal from duplicate wells (RFU), as well as S:B, computed as the signal ratio from DNA-containing (50 nM
ds DNA) versus buffer-only (i.e. without DNA) wells. B) Shown as examples are the effects of thiolactomycin (left) and mitoxantrone (right) on ThO
displacement (filled triangles, fluorescence signal normalized against DNA-free (0% relative fluorescence) and DNA-containing (100% relative
fluorescence) controls) or APE1 incision activity in the screening assay (filled squares).
doi:10.1371/journal.pone.0005740.g004
Figure 5. EndoIV counterscreen. Shown are examples of: (A, mitoxantrone) a molecule equally potent against APE1 and EndoIV and (B,6 -
hydroxy-DL-DOPA) an inhibitor with an apparent APE1 selectivity.
doi:10.1371/journal.pone.0005740.g005
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cleavage inhibition as determined in the radiotracer assay
generally tracked that observed in the fluorogenic screening
approach (as judged by the respective IC50 values): myricetin,
mitoxanthrone, 6-hydroxy-DL-DOPA and Reactive Blue 2
showed near complete inhibition (IC50,0.5 mM);
thiolactomycin, methyl 3,4-dephostatin and Tyrphostin AG 538
yielded an intermediate effect (IC50 in the 0.5–2 mM range); and
PPNDS, cephapirin sodium and ceftriaxone sodium were poorly
active (IC50.50 mM).
Taking into account the compilation of the results from the
experiments above, we excluded from further analysis mitoxan-
trone, because the compound operated largely as a DNA binder
and non-competitive inhibitor, and ATA, as the effect of this agent
likely stems from its ability to act as a DNA mimic and direct
competitor of nucleic acid processing enzymes in general [37]. We
also eliminated from further characterization PPNDS, cephapirin
sodium and ceftriaxone sodium, since they had at best weak, and
seemingly non-specific, inhibitory effects (summarized in Figure 3).
We performed more detailed analysis on myricetin, 6-hydroxy-
DL-DOPA, Reactive Blue 2, thiolactomycin, methyl 3,4-dephos-
tatin and Tyrphostin AG 538.
Inactivation of AP endonuclease activity in whole cell
extracts
Since APE1 comprises .95% of the total AP endonuclease
activity in mammals [38], most, if not all, THF incision observed
in human whole cell extracts is the result of APE1-dependent
cleavage. Thus, as another means of assessing the specificity of
candidate APE1 inhibitors, and to begin to evaluate their potential
biological value, we generated whole cell protein extracts from
HEK 293T and HeLa cells and determined the effect of the most
promising actives on total AP site cleavage activity [39]. Inhibitors
with specificity for APE1 were expected to impart a reduced
incision capacity relative to the control (no inhibitor, DMSO
control) reaction, even amidst all the non-specific proteins in the
extract. Indeed, 6-hydroxy-DL-DOPA and the arylstibonic acid
derivative NSC-13755 (used largely as a control, but not
previously tested in a whole cell extract assay) showed complete
inhibition at 100 mM; Reactive Blue 2 and myricetin displayed
potent inhibition ($80%); and Tyrphostin AG 538 displayed mild
inhibition against the HEK 293T and HeLa protein extracts
(Figure 7). Thiolactomycin and methyl 3,4-dephostatin had no
effect on total AP site cleavage activity of either extract.
Enhancement of MMS cytotoxicity and genotoxicity
As an additional means of examining the biological potential of
the APE1 inhibitors displaying the most promise in the assays
above, we evaluated the ability of 6-hydroxy-DL-DOPA, Reactive
Blue 2 and myricetin to enhance cellular sensitivity to the
alkylating agent MMS. MMS creates methylated base damage,
which is either lost spontaneously or excised by the alkylpurine
DNA glycosylase, resulting in a high number of cytotoxic abasic
sites [2]. We compared the colony formation efficiency of HeLa
cells exposed to MMS alone, one of the inhibitors alone, or a
combination of MMS plus inhibitor relative to a non-exposed
control. The combination of MMS and either of the inhibitors
resulted in a greater than additive increase in the percent cell
killing relative to the alkylator or inhibitor alone (at doses pre-
determined to elicit minimal cytotoxicity; Figure 8A), suggesting a
synergistic effect of these compounds on MMS lethality, as would
be expected for APE1 inactivation [10].
As a more direct means of evaluating the effect of 6-hydroxy-
DL-DOPA, Reactive Blue 2 and myricetin on APE1 activity in
vivo, we measured the level of AP sites in chromosomal DNA from
HeLa cells following one of the aforementioned treatment schemes
using an established aldehyde reactive probe-based colorimetric
assay [40]. These studies revealed that exposure to 6-hydroxy-DL-
DOPA, Reactive Blue 2 or myricetin alone (at 5 mM) increased AP
site damage relative to the control cells, and that each of the
compounds potentiated the genotoxic potential of MMS, support-
ing targeted inactivation of APE1 repair function by these
bioactives.
Predicted binding of inhibitors in APE1 active site
Molecular docking enables the evaluation of preferred binding
orientation and affinity of small molecules to their protein targets.
In an attempt to understand the possible interaction modes of the
Figure 6. Radiotracer validation assay. APE1 incision of a
32P-labeled DNA substrate was measured following incubation with the indicated
candidate inhibitor at 100 mM. Shown is a representative image of a denaturing polyacrylamide gel after resolution of the intact substrate from the
smaller reaction products (denoted). APE1=no inhibitor, DMSO control; PPNDS=PPNDS tetrasodium; CTR=ceftriaxone sodium; CEP=cephapirin
sodium; THIO=thiolactomycin; ME3-4=methyl-3,4-dephostatin; AG538=Tyrphostin AG 538; RB2=Reactive Blue 2; DOPA=6-hydroxy-DL-DOPA;
MYRI=myricetin; MITO=mitoxantrone.
doi:10.1371/journal.pone.0005740.g006
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Methods). Using the available X-ray crystal structure of APE1
complexed with substrate DNA (PDB code: 1DE9), docking of 6-
hydroxy-DL-DOPA into the APE1 binding site revealed that the
sugar phosphate pocket can easily accommodate the aromatic
moiety of the compound (Figure 9). The phenyl core fits in the
hydrophobic pocket, which is bordered by active site residues
Phe266, Trp280 and Leu282, known to complex with the abasic
ring structure. The two oxygen atoms of the carboxylic acid
moiety of 6-hydroxy-DL-DOPA are able to interact with both
metal ion (Mn
2+) and the catalytic residue Glu96 in a similar
position to the corresponding DNA phosphate in the co-crystal
structure. The 4-hydroxyl of the molecule can potentially
hydrogen-bond with either the side chain oxygen of Asn229 or
the backbone carbonyl oxygen of Ala230, while the primary amine
is involved in a hydrogen bond with the side chain oxygen of
Asn212. In addition, the phenyl ring of 6-hydroxy-DL-DOPA
could form a parallel-displaced pi stacking interaction to Phe266
and an edge-to-face pi stacking to Trp280.
We also performed docking experiments on Reactive Blue 2 and
myricetin; however, it was impossible to arrive at preferred
binding orientations for these two compounds likely due to their
structural features. Reactive Blue 2 is a bulky molecule containing
multiple anchoring groups (sulfonic acids and aminotriazine), all of
which could potentially interact with the metal ion in the APE1
active site, while myricetin is a rigid molecule lacking anchoring
groups, resulting in numerous possibilities of docking orientations
without shape complementarity conflicts.
Discussion
Small molecule protein modulators are viewed as the perfect
complement to frequently-used techniques such as RNAi and gene
knockout. In addition, the scientific and medical communities
have become increasingly interested in the design of small
molecule inhibitors of DNA repair, with the potential of improving
the therapeutic efficacy of clinical DNA-interactive drugs [1].
While there have been reports of small molecules directed at APE1
[10,13,14,15,39,41], the utility of these inhibitors has been
brought into doubt given (a) the inability to reproduce their
effectiveness [14] (and our unpublished observations) or (b) the
failure of the compounds to elicit a cellular consequence [15]. We
describe herein (i) the development of a panel of complementary
and improved miniaturized high-throughput screening and
profiling assays, which we believe will have broad appeal to other
investigators, and (ii) the identification of novel small molecule
APE1 inhibitors, which represent initial chemotypes in the long-
term endeavor of creating new targeted pharmaceuticals.
We outline within a robust APE1 screening assay that integrates
TAMRA (a bright, pH-insensitive analogue of rhodamine) as the
red-shifted fluorophore and BHQ-2 as the non-emitting dark
quencher. While the FAM/DABCYL arrangement remains a
convenient and largely appropriate choice in genotyping applica-
tions, its use in configuring small molecule screens is more
problematic. In particular, in a recently performed profiling study,
we found that up to 5% of the NIH Small Molecule Repository
(MLSMR, https://mli.nih.gov/mli/mlsmr/) exhibited strong
fluorescence in the blue-shifted UV light region (excitation near
350 nm, emission near 450 nm), and up to 0.2% of the diverse
small molecule collection interfered with fluorescein-like detection
(excitation near 480 nm, emission near 530 nm). Conversely, the
incidence of compounds capable of interfering with detection in
the red-shifted region (e.g, excitation around 550 nm and emission
near 590 nm) diminished to below 0.01% [27]. Moreover, the
combination of BHQ-2 with TAMRA resulted in a twofold
improvement in the signal to noise ratio relative to the comparable
FAM/DABCYL pair, and was better quenched in its dark state.
We note that the implemented real-time fluorescence monitoring
(kinetic read) to derive reaction rates also makes the TAMRA/
BHQ-2 assay less susceptible to variations in the screening
Figure 7. Effect of top APE1 inhibitors on AP site incision activity of whole cell extracts. Whole cell protein extracts from either HEK 293T
or HeLa cells (denoted) were exposed to the indicated inhibitor at 100 mM prior to measuring DNA strand cleavage activity via the radiolabeled
substrate assay. See Figure 7 for details and abbreviations; NSC-13755=the arylstibonic derivative.
doi:10.1371/journal.pone.0005740.g007
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which may interfere with detection [30]. It is anticipated that the
reconfigured APE1 assay described here will serve as a useful guide
to future investigations aimed at screening other nucleic acid
processing enzymes.
The concentration-response screen of the LOPAC collection
yielded a number of previously-unreported APE1 inhibitors. The
most potent hit was ATA, which inactivated the enzyme
consistently in the low nanomolar range. While very effective,
ATA has been noted to exist as a stable radical homopolymer of
varying length and to act as a strong inhibitor of a large number of
DNA- and RNA-processing enzymes [37,42,43]. As such, ATA
did not represent a chemotype of value to study APE1 function.
The other top hits (summarized in Figure 3) comprised a diverse
group of compounds and included small molecules with potent
inhibitory potential, such as 6-hydroxy-DL-DOPA, thiolactomycin
and methyl 3,4-dephostatin, several larger-size comparatively
weak inhibitors, such as PPNDS tetrasodium and ceftriaxone
sodium, and suspected DNA binders, such as mitoxantrone and
WB 64. Since a variety of factors, including promiscuous
aggregators, non-selective covalent modifiers and compounds that
sequester substrate molecules, can produce primary screening hits
that are not relevant [44], we developed and implemented a panel
of secondary assays to run against a subset of initial hits or the
entire LOPAC collection.
As a means of interrogating the primary screening hits, and to
gain further insight into their mechanism of action, we employed a
fluorescent dye-displacement assay [22], substituting the frequent-
ly-used ethidium bromide with the more sensitive and robust
reporter ThO. In a screen of the LOPAC collection against a
ThO-substrate DNA complex, all annotated fluorescent DNA
intercalators within the library, e.g. idarubicin, doxorubicin and
distamycin, displayed strong displacement activity. Furthermore,
the non-fluorescent APE1 screening hits WB 64 and mitoxantrone
exhibited dye-displacement IC50 values similar to or better than
those displayed in the APE1 enzymatic incision assay. This
behavior is reminiscent of an indirect, non-competitive DNA
binding effect and is consistent with the multiple fused ring
Figure 8. Effect of top APE1 inhibitors on cytotoxic and genotoxic potential of MMS. A) HeLa cells were exposed to control/mock
conditions (cntrl), MMS alone, inhibitor (Inh) alone, or both inhibitor and MMS as indicated. Plotted is the average and standard deviation of the
percent colony survival relative to the control for three independent data points. B) HeLa cells were exposed to the different conditions outlined in
panel A (except only at 5 mM inhibitor), and total genomic AP sites were measured. Shown is the average and standard deviation of five independent
measurements of the number of AP sites per 10
6 base pairs.
doi:10.1371/journal.pone.0005740.g008
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both molecules. On the other hand, APE1 inhibitor molecules that
lacked obvious DNA-binding features (i.e. fused aromatic ring
structures or positively charged groups), such as thiolactomycin
and Tyrphostin AG 538, yielded weak or no displacement activity.
These findings support the ThO displacement assay as a
convenient counterscreen to exclude DNA binders from further
consideration, and the complete results with the LOPAC
1280 are
available in the corresponding PubChem deposition (AID 1707).
To further probe the selectivity of the inhibitors identified in the
APE1 qHTS, we tested the LOPAC collection against E. coli
EndoIV. AP endonucleases are sub-classified into two major
superfamilies based on homology to either E. coli exonuclease III
(ExoIII) or E. coli EndoIV [36]. While members of the two
superfamilies exhibit similar biochemical properties, such as AP
endonuclease activity, there exists no sequence or structural
homology between the different superfamily constituents. Since
APE1 is an ExoIII family member, it was anticipated that
inhibitors specific for human APE1 would not exert an effect on E.
coli EndoIV. The screen of the LOPAC
1280 against EndoIV under
conditions identical to those used in the APE1 screen resulted in
relatively few hits, most of which had low potency. Among the
actives shared between the two endonucleases were the non-
specific DNA binders mitoxantrone and WB 64, whereas
compounds with selectivity to APE1 included thiolactomycin, 6-
hydroxy-DL-DOPA, methyl 3,4-dephostatin, myricetin and Re-
active Blue 2. The fact that the EndoIV screen did not identify
either potent (other than Tyrphostin AG 538; Figure 3) or
EndoIV-selective hits may suggest an active site for this enzyme
that is hard to access. Our ongoing studies of inhibitors for E. coli
EndoIV are outside the scope of the present investigation and will
be the subject of a separate report.
Finally, we tested the top screening hits in a standard
radiotracer incision assay. All of the selected inhibitors, except
those possessing the highest IC50 values (i.e. PPNDS tetrasodium,
cephapirin sodium and ceftriaxone sodium), yielded dose-depen-
dent inhibition of APE1 in the gel-based assay, validating the
present screening approach and indicating that the TAMRA/
Figure 9. Molecular Modeling. Left panel: ribbon representation of APE1 structure with DNA bound (PDB code: 1DE9); DNA is shown in cyan; the
active site is marked within the box. Upper right panel: docking pose of 6-hydroxy-DL-DOPA in APE1 active site; potential hydrogen-bonds are
labeled in yellow lines with distances, selected active site amino acid residues are indicated. See text for details. Lower right panel: APE1 binding
pocket is depicted by molecular surface representation.
doi:10.1371/journal.pone.0005740.g009
Bioactive Inhibitors of APE1
PLoS ONE | www.plosone.org 11 June 2009 | Volume 4 | Issue 6 | e5740BHQ-2 assay is relatively insensitive to false-positive compounds
acting via fluorescence interference.
As a step towards determining the biological potential of the
top, validated APE1 inhibitors from the profiling assays above, we
explored the ability of 6-hydroxy-DL-DOPA, Reactive Blue 2,
myricetin, Tyrphostin AG 538, thiolactomycin, methyl 3,4-
dephostatin and NSC-13755 to inactivate AP site cleavage activity
of protein extracts from HEK 293T and HeLa cells. Of these
compounds, 6-hydroxy-DL-DOPA, Reactive Blue 2 and myricetin
had the most pronounced effect, leading to a significant reduction
in total AP site cleavage activity, even amidst the pool of non-
specific proteins. NSC-13755 also displayed potent inhibitory
potential, but had been shown to fail in cell-based experiments
[15]. The known bioactives Reactive Blue 2, 6-hydroxy-DL-
DOPA and myricetin were subsequently demonstrated to enhance
the cytotoxic and genotoxic potential of the alkylating agent MMS
in cell culture assays, indicating specificity for APE1 and
exemplifying their prospect as biological probes for APE1
function.
While our manuscript was under preparation, a report came out
describing the identification of APE1 inhibitors using a virtual
screen with a set of three-dimensional pharmacophore models
generated based on key interactions of abasic DNA with the
enzyme active site [45]. Notably, the inhibitors uncovered shared a
few common features, including the requirement of at least one
negatively ionizable (NI) group; the most potent inhibitors
possessed two such groups separated by a hydrophobic core.
Several hits identified in our screen are compatible with these
findings. Among them is ATA, which contains dicarboxylates in
close proximity similar to the more potent inhibitors reported [45],
as well as a third carboxylate group that may augment the polar
interactions within the APE1 active site; the diphenylmethylene
core of ATA may occupy the hydrophobic pocket of the protein,
as outlined in the authors’ model [45]. In addition, 6-hydroxy-DL-
DOPA, and the weaker inhibitors cephapirin and ceftriaxone,
contain a single carboxylate, along with a relatively hydrophobic
core decorated with various H-bond acceptor or donor combina-
tions.
However, a consequence of utilizing interactions of abasic DNA
with key APE1 active site residues to build the pharmacophore
models is the potential to bias the results of the virtual compound
database search. In particular, most of the models yielded
compounds containing at least one carboxylate or bioisoteres that
mimicked the NI group found in the phosphodiester backbone of
DNA [45]. Their success in retrieving APE1 inhibitors led to the
conclusion that design of potent, therapeutically relevant inhibitors
must contain the features discussed above [45]. Yet, our screen of
a diverse set of pharmacologically known actives unveiled more
structurally diverse and potent inhibitors that do not appear to fit
the pharmacophore models. An example is thiolactomycin, which
did not share any of the ‘‘required’’ features. Furthermore, the
strong effect observed with Reactive Blue 2, which contains no
carboxylates, but instead possesses three readily ionizable sulfonate
moieties, two of which are separated by a hydrophobic stretch,
indicates that the requirement for a carboxyl substituent is not
absolute. Although carboxylate containing compounds are likely to
be prevalent among APE1 inhibitors, our screening results suggest
that alternate interactions in the binding site may provide
additional opportunities for the design of potent and selective
endonuclease inhibitors. An example of this is 6-hydroxy-DL-
DOPA, for which our modeling studies indicate that significant pi
stacking interactions can occur between a ligand and the protein’s
sugar phosphate binding pocket. Such an interaction mode is
different from the pharmacophore model developed by Zawahir et
al [45], indicating a possibly new guiding principle for the design
of small molecule inhibitors of APE1.
The most effective APE1 inhibitors within, i.e. Reactive Blue 2,
6-hydroxy-DL-DOPA and myricetin, were identified from the
LOPAC
1280, a collection of 1280 bioactive compounds represent-
ing 56 pharmacological classes. Such results point to APE1 as a
novel target for these biomolecules and substantiate this repair
endonuclease as a pharmacological target going forward. Reactive
Blue 2 and its analogues are known to occupy the nucleotide-
binding sites of a variety of proteins [46], and Reactive Blue 2 has
been documented to be a selective antagonist of certain subtypes of
P2Y receptors [47,48]. It is possible that the inhibitory effect of
Reactive Blue 2 on APE1 occurs via a similar active site occupancy
mechanism [49], consistent with the recent report that free
nucleotides (e.g. ATP) can regulate APE1 endonuclease efficiency
[28]. 6-hydroxy-DL-DOPA is a precursor of the catecholaminer-
gic neurotoxin 6-hydroxydopamine, and some of its reported
neurotoxic effects may arise due to the inhibition of APE1 repair
function [50]. Myricetin is a major flavonol, naturally occurring in
a variety of vegetables, fruits and berries, as well as in beverages
such as tea and wine [51,52]. Myricetin exhibits several
pharmacological benefits, and its antioxidant properties are
thought to contribute to its cancer-preventive effects. However,
myricetin has also been shown to induce DNA damage and
promote mutagenesis in the Ames Test [53]. Myricetin appears to
have several molecular targets, including thioredoxin reductase
[54], mitogen-activated protein kinase kinase MEK1 [55],
enzymes involved in the redox metabolism of polycyclic aromatic
hydrocarbons [56], DNA and RNA polymerases, and in some
instances topoisomerases [52], and the present study adds APE1 to
this list.
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